1. Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study
- Author
-
Habte, Yimer, Jason, Melear, Edward, Faber, William I, Bensinger, John M, Burke, Mohit, Narang, Don, Stevens, Kathleen S, Gray, Yana, Lutska, Padma, Bobba, Keqin, Qi, Daniela, Hoehn, Ming, Qi, Thomas S, Lin, and Robert M, Rifkin
- Subjects
Bortezomib ,Cancer Research ,Oncology ,Antineoplastic Combined Chemotherapy Protocols ,Antibodies, Monoclonal ,Humans ,Hematology ,Multiple Myeloma ,Cyclophosphamide ,Dexamethasone - Abstract
In the primary analysis of LYRA, daratumumab + cyclophosphamide/bortezomib/dexamethasone (DARA + CyBorD) was effective and well tolerated in newly diagnosed multiple myeloma (NDMM) and relapsed multiple myeloma (RMM). We report the final analysis of LYRA (median months of follow-up: NDMM, 35.7; RMM, 35.3) after all patients completed study therapy, were followed for 36 months, or discontinued. Patients received DARA + CyBorD induction, autologous stem cell transplant (if eligible), and 12 months of daratumumab maintenance. Eighty-seven NDMM patients enrolled, 39 underwent transplant, and 63 completed maintenance. Rates of complete response or better were 48.7% and 29.8% for NDMM transplant and NDMM non-transplant patients, respectively, and 36-month progression-free survival rates were 69.3% and 72.6%. Grade 3/4 treatment-emergent adverse events occurred in 61.6% of NDMM patients. Efficacy and safety data are also reported for the smaller RMM cohort (
- Published
- 2022